These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

539 related items for PubMed ID: 29427492

  • 21. Nonalcoholic fatty liver disease: diagnosis, pathogenesis, and management.
    Başaranoğlu M, Örmeci N.
    Turk J Gastroenterol; 2014 Apr; 25(2):127-32. PubMed ID: 25003670
    [Abstract] [Full Text] [Related]

  • 22. Review article: Drug therapy for non-alcoholic fatty liver disease.
    Comar KM, Sterling RK.
    Aliment Pharmacol Ther; 2006 Jan 15; 23(2):207-15. PubMed ID: 16393299
    [Abstract] [Full Text] [Related]

  • 23. Metabolic inflammation as an instigator of fibrosis during non-alcoholic fatty liver disease.
    Katsarou A, Moustakas II, Pyrina I, Lembessis P, Koutsilieris M, Chatzigeorgiou A.
    World J Gastroenterol; 2020 May 07; 26(17):1993-2011. PubMed ID: 32536770
    [Abstract] [Full Text] [Related]

  • 24. Role of non-steroidal anti-inflammatory drugs on intestinal permeability and nonalcoholic fatty liver disease.
    Utzeri E, Usai P.
    World J Gastroenterol; 2017 Jun 14; 23(22):3954-3963. PubMed ID: 28652650
    [Abstract] [Full Text] [Related]

  • 25. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Chow MD, Lee YH, Guo GL.
    Mol Aspects Med; 2017 Aug 14; 56():34-44. PubMed ID: 28442273
    [Abstract] [Full Text] [Related]

  • 26. Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-Alcoholic Fatty Liver Disease in Thailand.
    Chongmelaxme B, Phisalprapa P, Sawangjit R, Dilokthornsakul P, Chaiyakunapruk N.
    Pharmacoeconomics; 2019 Feb 14; 37(2):267-278. PubMed ID: 30430467
    [Abstract] [Full Text] [Related]

  • 27. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
    Zoller H, Tilg H.
    Metabolism; 2016 Aug 14; 65(8):1151-60. PubMed ID: 26907206
    [Abstract] [Full Text] [Related]

  • 28. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y, Sugimoto K, Inui H, Fukusato T.
    World J Gastroenterol; 2015 Apr 07; 21(13):3777-85. PubMed ID: 25852263
    [Abstract] [Full Text] [Related]

  • 29. Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease.
    Ganesh S, Rustgi VK.
    Clin Liver Dis; 2016 May 07; 20(2):351-64. PubMed ID: 27063274
    [Abstract] [Full Text] [Related]

  • 30. Treatment of non-alcoholic fatty liver disease.
    Dyson J, Day C.
    Dig Dis; 2014 May 07; 32(5):597-604. PubMed ID: 25034293
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Nonalcoholic Fatty Liver Disease: Pathophysiology and Management.
    Carr RM, Oranu A, Khungar V.
    Gastroenterol Clin North Am; 2016 Dec 07; 45(4):639-652. PubMed ID: 27837778
    [Abstract] [Full Text] [Related]

  • 34. Natural antioxidants for non-alcoholic fatty liver disease: molecular targets and clinical perspectives.
    Salomone F, Godos J, Zelber-Sagi S.
    Liver Int; 2016 Jan 07; 36(1):5-20. PubMed ID: 26436447
    [Abstract] [Full Text] [Related]

  • 35. Current Treatment of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
    Hung CK, Bodenheimer HC.
    Clin Liver Dis; 2018 Feb 07; 22(1):175-187. PubMed ID: 29128055
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats.
    Hayashizaki-Someya Y, Kurosaki E, Takasu T, Mitori H, Yamazaki S, Koide K, Takakura S.
    Eur J Pharmacol; 2015 May 05; 754():19-24. PubMed ID: 25701721
    [Abstract] [Full Text] [Related]

  • 38. [Non-alcoholic fatty liver disease and steatohepatitis].
    Pár G, Horváth G, Pár A.
    Orv Hetil; 2013 Jul 21; 154(29):1124-34. PubMed ID: 23853345
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.